{"disease":{"id":"nsclc-advanced-non-small-cell-lung-cancer","name":"nsclc advanced non small cell lung cancer"},"drugs":{"marketed":[],"pipeline":[],"offLabel":[],"totalMarketed":0,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT06613633","title":"Third-generation EGFR-TKI Treatment in Metastatic EGFR-mutant NSCLC","phase":"","overall_status":"COMPLETED","enrollment_count":4000,"lead_sponsor_name":"Fudan University","has_results":false},{"nct_id":"NCT06604689","title":"AI-guided Prognostication and Cranial Radiotherapy Optimization in EGFR-TKI-treated Non-small Cell Lung Cancer Patients With Baseline Brain Metastases","phase":"","overall_status":"RECRUITING","enrollment_count":800,"lead_sponsor_name":"Fudan University","has_results":false},{"nct_id":"NCT07150598","title":"Immune-Marker Platform for Patients With Advanced Lung Cancer","phase":"","overall_status":"NOT_YET_RECRUITING","enrollment_count":500,"lead_sponsor_name":"Technische Universität Dresden","has_results":false},{"nct_id":"NCT07288632","title":"Effects of Genomic Profiles on Thromboembolic Risk in Patients With Locally Advanced or Metastatic Non-small-cell Lung Cancer","phase":"","overall_status":"RECRUITING","enrollment_count":500,"lead_sponsor_name":"University Of Perugia","has_results":false},{"nct_id":"NCT07524257","title":"ResQ1010-NSCLC: NAI + Chemoimmunotherapy vs Chemoimmunotherapy for First-Line Advanced/Metastatic NSCLC","phase":"PHASE3","overall_status":"NOT_YET_RECRUITING","enrollment_count":494,"lead_sponsor_name":"ImmunityBio, Inc.","has_results":false},{"nct_id":"NCT06881784","title":"Study of Daraxonrasib (RMC-6236) in Patients With RAS Mutated NSCLC (RASolve 301)","phase":"PHASE3","overall_status":"RECRUITING","enrollment_count":420,"lead_sponsor_name":"Revolution Medicines, Inc.","has_results":false},{"nct_id":"NCT07400575","title":"Anlotinib in Cross-line Treatment of NSCLC and SCLC","phase":"","overall_status":"NOT_YET_RECRUITING","enrollment_count":350,"lead_sponsor_name":"Henan Cancer Hospital","has_results":false},{"nct_id":"NCT07491211","title":"Osimertinib Combined With Intracranial SRT for EGFR-Mutant NSCLC With Symptomatic Brain Metastases","phase":"","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":300,"lead_sponsor_name":"Fudan University","has_results":false},{"nct_id":"NCT06954259","title":"Prognostic Correlation Between the Ratio of the Neutrophil Ratio to the Ratio of CD4+/CD8+ T Cells in Patients With Advanced Non-small Cell Lung Cancer NSCLC) Undergoing Immunotherapy Combined With Chemotherapy","phase":"","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":272,"lead_sponsor_name":"Qiang Xu","has_results":false},{"nct_id":"NCT07371663","title":"An Phase Ib/II Clinical Trial of TCC1727 Combination Therapy in Advanced Solid Tumors","phase":"PHASE1, PHASE2","overall_status":"RECRUITING","enrollment_count":266,"lead_sponsor_name":"Beijing Tide Pharmaceutical Co., Ltd","has_results":false},{"nct_id":"NCT06706076","title":"A Study of BH-30643 in Subjects With Locally Advanced or Metastatic NSCLC Harboring EGFR and/or HER2 Mutations","phase":"PHASE1, PHASE2","overall_status":"RECRUITING","enrollment_count":266,"lead_sponsor_name":"BlossomHill Therapeutics","has_results":false},{"nct_id":"NCT05652868","title":"Clinical Study of Antibody-Drug Conjugate MYTX-011 in Subjects With Non-Small Cell Lung Cancer","phase":"PHASE1","overall_status":"TERMINATED","enrollment_count":227,"lead_sponsor_name":"Mythic Therapeutics","has_results":false},{"nct_id":"NCT07121387","title":"A Retrospective Cohort Analysis of SMARCA4-Deficient Lung Cancer","phase":"","overall_status":"COMPLETED","enrollment_count":221,"lead_sponsor_name":"Shanghai Pulmonary Hospital, Shanghai, China","has_results":false},{"nct_id":"NCT05364073","title":"Study of Furmonertinib in Patients With Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) With Activating, Including Uncommon, Epidermal Growth Factor Receptor (EGFR) or Human Epidermal Growth Factor Receptor 2 (HER2) Mutations","phase":"PHASE1","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":160,"lead_sponsor_name":"ArriVent BioPharma, Inc.","has_results":false},{"nct_id":"NCT07469488","title":"A Clinical Trial on the Outcomes of Comprehensive Enhanced Prophylaxis Management (CEPM) in Chinese Patients With EGFR-Mutated Advanced NSCLC Receiving Amivantamab-Based Regimens","phase":"PHASE4","overall_status":"NOT_YET_RECRUITING","enrollment_count":122,"lead_sponsor_name":"Shanghai Pulmonary Hospital, Shanghai, China","has_results":false},{"nct_id":"NCT07478809","title":"A Retrospective Real-World Study Based on RATIONALE-307","phase":"","overall_status":"RECRUITING","enrollment_count":109,"lead_sponsor_name":"Cancer Institute and Hospital, Chinese Academy of Medical Sciences","has_results":false},{"nct_id":"NCT07262671","title":"Predictive Value of Exosomes in Pleural Effusion for Advanced Lung Cancer","phase":"","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":100,"lead_sponsor_name":"Fudan University","has_results":false},{"nct_id":"NCT07330596","title":"QL1706 Combined With Chemotherapy in the Treatment of Immune-mediated NSCLC","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":96,"lead_sponsor_name":"Anhui Provincial Cancer Hospital","has_results":false},{"nct_id":"NCT06653023","title":"Universal CAR-T Cells (REVO-UWD-03) for Advanced Hepatocellular Carcinoma and Lung Cancer","phase":"EARLY_PHASE1","overall_status":"RECRUITING","enrollment_count":60,"lead_sponsor_name":"Wondercel Biotech (ShenZhen)","has_results":false},{"nct_id":"NCT07486648","title":"Osimertinib Plus Capivasertib in NSCLC With PIK3CA/AKT1/PTEN Alterations Following Prior 1L Osimertinib","phase":"PHASE1, PHASE2","overall_status":"NOT_YET_RECRUITING","enrollment_count":53,"lead_sponsor_name":"Shanxi Province Cancer Hospital","has_results":false},{"nct_id":"NCT07356544","title":"Observational, Prospective, Multi-centric Study Exploring HER2 Mutations Incidence and Therapeutic Management in aNSCLC","phase":"","overall_status":"RECRUITING","enrollment_count":50,"lead_sponsor_name":"Gruppo Oncologico Italiano di Ricerca Clinica","has_results":false},{"nct_id":"NCT07250386","title":"A Study of CEA-Targeted CAR-T Therapy in Patients With CEA-Positive Advanced Solid Tumors","phase":"PHASE1","overall_status":"RECRUITING","enrollment_count":48,"lead_sponsor_name":"Second Affiliated Hospital, School of Medicine, Zhejiang University","has_results":false},{"nct_id":"NCT07158489","title":"Overcoming Resistance to Immunotherapy Combining Gemcitabine With Ivonescimab in Advanced NSCLC","phase":"PHASE2","overall_status":"NOT_YET_RECRUITING","enrollment_count":47,"lead_sponsor_name":"Swiss Cancer Institute","has_results":false},{"nct_id":"NCT07343479","title":"Sacituzumab Tirumotecan Plus Third-Generation TKI With/Without Radiotherapy for EGFR-Mutant NSCLC Brain Metastases","phase":"PHASE2","overall_status":"NOT_YET_RECRUITING","enrollment_count":45,"lead_sponsor_name":"Zhejiang Cancer Hospital","has_results":false},{"nct_id":"NCT05303493","title":"Camu-Camu Prebiotic and Immune Checkpoint Inhibition in Patients With Non-small Cell Lung Cancer and Melanoma","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":45,"lead_sponsor_name":"Centre hospitalier de l'Université de Montréal (CHUM)","has_results":false},{"nct_id":"NCT07348965","title":"Pulsatile High-dose Furmonertinib in EGFR-mutant NSCLC With Leptomeningeal Metastasis","phase":"NA","overall_status":"RECRUITING","enrollment_count":42,"lead_sponsor_name":"Guangzhou University of Traditional Chinese Medicine","has_results":false},{"nct_id":"NCT04846452","title":"Sintilimab, Anlotinib Hydrochloride and Platinum-Containing Dual-Agent Chemotherapy in NSCLC","phase":"PHASE2","overall_status":"UNKNOWN","enrollment_count":40,"lead_sponsor_name":"The First Affiliated Hospital with Nanjing Medical University","has_results":false},{"nct_id":"NCT06731413","title":"Reduced CT + Anti-PD-1 as First Line Tx in Vulnerable Older Adults w/Adv <50% PD-L1 Non-Small Cell Lung Cancer (NSCLC)","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":40,"lead_sponsor_name":"Virginia Commonwealth University","has_results":false},{"nct_id":"NCT07353476","title":"Radiotherapy Plus Anti-PD-1 Versus Anti-PD-1 Alone in ypTanyN⁺M0 NSCLC","phase":"PHASE2","overall_status":"NOT_YET_RECRUITING","enrollment_count":38,"lead_sponsor_name":"Shanghai Zhongshan Hospital","has_results":false},{"nct_id":"NCT07361237","title":"A Phase l Clinical Study to Evalute the Safety,Tolerability,Pharmacokinetic Characteristics,and Preliminary Anti-tumor Efficacy of HJ-004-02 Tablets in Patients With Non-squamous Non-small Cell Lung Cancer With Epidermal Growth Factor Receptor (EGFR) Mutations","phase":"PHASE1","overall_status":"RECRUITING","enrollment_count":36,"lead_sponsor_name":"Tongji University","has_results":false},{"nct_id":"NCT06896890","title":"Cisplatin (CIS) Administered As Dry Powder for Inhalation (DPI) in Patients with Stage IV Non-Small Cell Lung Cancer","phase":"PHASE1, PHASE2","overall_status":"RECRUITING","enrollment_count":32,"lead_sponsor_name":"Inhatarget Therapeutics","has_results":false},{"nct_id":"NCT06823258","title":"Pharmacokinetic Study of HS-10365 Capsule in Subjects with Hepatic Impairment and Normal Hepatic Function","phase":"PHASE1","overall_status":"NOT_YET_RECRUITING","enrollment_count":32,"lead_sponsor_name":"Jiangsu Hansoh Pharmaceutical Co., Ltd.","has_results":false},{"nct_id":"NCT07259447","title":"Efficiency of Contemporary Off-line Adaptive Radiotherapy for Lung Cancer","phase":"NA","overall_status":"RECRUITING","enrollment_count":30,"lead_sponsor_name":"Universitaire Ziekenhuizen KU Leuven","has_results":false},{"nct_id":"NCT06951399","title":"Tracking T-Cell Responses to Evaluate Pembrolizumab Effectiveness in Advanced Non-Small Cell Lung Cancer","phase":"PHASE2","overall_status":"NOT_YET_RECRUITING","enrollment_count":30,"lead_sponsor_name":"Rabin Medical Center","has_results":false},{"nct_id":"NCT07528274","title":"Microwave Ablation Plus Tislelizumab and Docetaxel in Advanced NSCLC After First-Line Immunotherapy Failure","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":20,"lead_sponsor_name":"Tianjin Medical University Cancer Institute and Hospital","has_results":false}],"total":35},"guidelines":[],"source":"Drug Landscape verified database"}